Canton Strategic Holdings, Inc. (NASDAQ: CNTN)

Canton Strategic Holdings, Inc. operates as a dual-focus company combining biotechnology research and development with digital asset treasury management centered on the Canton Network and its native utility token, Canton Coin (CC). The company pursues therapeutic candidates in immunology and inflammation while simultaneously participating as a Super Validator and strategic investor in the Canton Network ecosystem to advance institutional blockchain adoption. This strategic shift in November 2025 prioritized disciplined digital asset treasury management and investment in the Canton Network, building on prior biotech operations from 2022 through late-2025.

Revenue generation stems from two primary activities: potential future commercialization of biologic therapeutic candidates and earnings from digital asset treasury strategy components. The biotech segment aims to generate revenue through FDA approval and commercialization of product candidates like GV104 and GV023, targeting military, first responder, and patient populations with high unmet medical needs. The digital asset strategy generates recurring protocol-based validation rewards in CC from validator operations, potential yields from CC lending and secured financing, income from derivative strategies such as selling options, and strategic investments in applications and middleware that increase Canton Network utilization and transaction activity.

The company operates through the following segments: Biotechnology Research and Development and Digital Asset Treasury Strategy.

• Biotechnology Research and Development: This segment focuses on discovering, developing, and seeking regulatory approval for therapeutic candidates in inflammatory and immunologic conditions with high unmet need. It operates through the subsidiary Gravitas, which advances product candidates such as GV104 and GV023 toward clinical trials and potential FDA approval. The segment leverages patented technologies including transmucosal film compositions and polymeric nanoparticle platforms to develop novel drug delivery systems.

• Digital Asset Treasury Strategy: This segment manages the company's strategic reserve of Canton Coin (CC) and executes activities to support and benefit from the Canton Network ecosystem. It includes operating as a Super Validator and running additional validator nodes to earn protocol-based validation rewards in CC while contributing to network security and governance. The segment also involves building, sponsoring, or investing in applications and middleware compatible with the Canton Network, collaborating with ecosystem participants, engaging in CC locking, lending, and options strategies, and participating in the Canton Foundation Board to influence network governance and tokenomics.

Canton Strategic Holdings, Inc. occupies a distinctive position at the intersection of biopharmaceutical innovation and institutional blockchain infrastructure, competing in both sectors with specialized approaches. In biotechnology, it faces competition from major pharmaceutical companies, established biotech firms, specialty drug developers, and academic research institutions developing therapies for immunologic and inflammatory conditions. Its competitive advantages include proprietary buccal film formulations like GV104 with extended half-life properties and oral anti-TNF-alpha candidates such as GV023 designed to improve patient adherence. In the digital asset space, it competes with other token holders, validator operators, digital asset treasury companies, and blockchain investment vehicles seeking exposure to the Canton Network, differentiating itself through its role as a Super Validator, Foundation Board member, and strategic investor in network-native applications that drive utility and adoption.

The company serves specialized customer bases across its two operational segments. In biotechnology, it targets military and first responder populations for prophylactic protection against synthetic opioid exposure through candidates like GV104, and patients with autoimmune diseases who require convenient self-administered therapies such as its oral infliximab candidate GV023. For its digital asset treasury strategy, Canton Strategic Holdings, Inc. engages with institutional participants in the Canton Network ecosystem including financial institutions, technology providers, application developers, and other Super Validators to advance network utilization, settlement efficiency, and interconnected workflows across capital markets.